Background/Purpose: To explore similarities and differences between rheumatologists (rheum), general practitioners (GP) and patients (pt) regarding the relevance of outcome parameters in polymyalgia rheumatica (PMR).
Methods: This study was part of the ACR/EULAR project for the development of guidelines for PMR. A candidate list of outcome parameters was identified by literature review and input from the guideline development group (GDG) involving rheum, GP and pt. The candidate item list contained 119 outcome measures including symptoms, physical examination findings, laboratory parameters, imaging, composite outcome measures, drug related adverse effects, functional status, quality of life and PMR related complications. A survey-based grading of the candidate outcomes was performed using SurveyMonkey®. We invited 43 rheum (15 with a special interest in PMR), 87 GP (all UK) and 43 pt (all UK) to rate each item based on its relative importance for clinical decisions on a 1-9 point scale (1-3 not important, 4-6 important, but not critical and 7-9 critical). We excluded the rating of a group if >33% of responders marked an item with “don’t know”.
Results:
Thirty-eight rheum (88%; 100% of those with special interest in PMR), 15 (17%) GP and 41 (95%) pt responded. Only 6 (5.0%) parameters were deemed as critical (score ≥7) by all groups [remission, relapse, duration of glucocorticoid (GC) therapy, discontinuation of GC therapy, development of GCA, osteoporosis].
General symptoms such as fatigue, malaise, sleep disturbances, depression or anxiety were more frequently rated as critical by pt (37.5-71.8%) than by rheum (0-26.3%, all p-values ≤0.01). Appraisal of fatigue and malaise was similar by GPs and rheum whereas sleep disturbance, depression and anxiety were similarly graded by GP and pt. Among laboratory and imaging parameters no significant differences between groups were observed mainly because several parameters were marked “don’t know” by a high proportion of pt and GP. GP (57.1%) considered healthcare resource use more relevant than rheum (26.3%, p=0.038) whereas a high proportion of pt did not know about this parameter. Functional status, impact on pt’s career, quality of life, mobility, self-care and usual activities were rated higher by pt (54.8-84.6%) than by rheum (23.7-44.7%, all p-values <0.01). Quality of life, impact on pt’s career, self-care and usual activities were also more relevant for GP (71.4-92.9%) than for rheum (all p-values <0.05).
Conclusion: These data demonstrate a higher relevance of general symptoms, functional status and quality of life to patients with PMR compared with rheumatologists. Ratings of outcome parameters from patients and general practitioners were less discordant than those from patients and rheumatologists.
Disclosure:
Y. Singh,
None;
C. Dejaco,
None;
S. Mackie,
None;
D. Ching,
None;
A. Bachta,
None;
A. Maharaj,
None;
A. Wagner,
None;
M. Lima,
None;
D. Jayne,
Roche Pharmaceuticals,
2,
Genetech,
2,
Mitshubishi,
5,
Takeda,
5,
Roche Pharmaceuticals,
5,
Roche Pharmaceuticals,
8;
K. Barraclough,
None;
C. D. Mallen,
None;
S. P. Merry,
None;
J. Hollywood,
None;
M. Whitlock,
None;
K. Gilbert,
None;
P. Hildreth,
None;
J. Nott,
None;
H. Padbury,
None;
J. Miller,
None;
L. Neill,
None;
D. Tronnier,
None;
P. Perel,
None;
A. Hutchings,
None;
D. Camellino,
None;
S. E. Carsons,
None;
W. Docken,
None;
C. Duftner,
None;
A. Abril,
None;
R. F. Spiera,
Roche Pharmaceuticals,
2,
Novartis Pharmaceutical Corporation,
2,
GlaxoSmithKline,
2;
C. T. Pease,
None;
A. P. Diamantopoulos,
None;
F. Buttgereit,
None;
P. V. Balint,
Abbvie(formerly Abbott), ESAOTE, Roche ,
2,
Abbvie(formerly Abbott), Egis, MSD, Philips, Pfizer, Richter ,
5,
Abbvie(formerly Abbott), Bristol-Myers Squibb, GE, MSD, Philips, Pfizer, Richter, UCB,
8;
E. Nordborg,
None;
L. Bianconi,
None;
B. Fashanu,
None;
S. Mori,
None;
V. M. Martínez-Taboada,
None;
M. C. Cid,
None;
W. A. Schmidt,
Actelion Pharmaceuticals US,
2,
Esaote,
2,
GE Healthcare,
2;
M. A. Cimmino,
None;
M. Schirmer,
None;
C. Salvarani,
None;
E. L. Matteson,
None;
B. Dasgupta,
None.
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/developing-guideline-for-polymyalgia-rheumatica-prioritisation-of-outcome-measures-perspective-of-patients-general-practitioners-and-rheumatologists/